Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | – | – | 74.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -369.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -350.2% |
| EPS Diluted | -0.19 | -0.34 | -0.45 | -0.52 |
| % Growth | 44.1% | 24.4% | 13.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |